GAITHERSBURG, Md., Jan. 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response that mimics natural biology, today announced the appointment of Grant Verstandig to its Board of Directors.

More:
NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh